Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.46 USD
+0.06 (2.50%)
Updated Apr 26, 2024 03:40 PM ET
After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPHA 2.46 +0.06(2.50%)
Will IPHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPHA
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
IPHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Other News for IPHA
Buy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential
Innate Pharma doses first patient in Sanofi-sponsored trial of SAR443579
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Innate Pharma: A Strong Buy on IPH45’s Promising Data and Solid Financial Projections